Pharmacokinetics

Pharmacokinetics is the branch of pharmacology concerned with the time course of drugs and their metabolites in the body. It investigates absorption, distribution, metabolism, and excretion—collectively known as ADME—and uses concentration measurements and mathematical models to describe these processes. Pharmacokinetics addresses how the body handles a drug, whereas pharmacodynamics addresses the drug’s biological effects; together, they connect administration, exposure, and response. (eur-lex.europa.eu)

Pharmacokinetic evidence supports drug development, comparisons between formulations, investigation of drug interactions, and characterization of differences among patients. Its principal approaches include noncompartmental analysis, compartmental modeling, population analysis, and physiologically based modeling. These approaches relate measurable quantities, such as blood concentrations and urinary recovery, to drug disposition while accounting for biological variability and uncertainty. Applications extend from conventional small-molecule medicines to therapeutic proteins and other complex products, whose disposition may require distinct experimental and modeling methods. (ema.europa.eu)

Scope and conceptual boundaries

Pharmacokinetics (PK) describes the time course of drugs and their metabolites in an organism, relating administered doses to concentrations in blood and other biological materials. Its principal processes are absorption, distribution, metabolism, and excretion, collectively abbreviated ADME. Drug disposition, in its narrower usage, comprises distribution and elimination after entry into the body; elimination includes both metabolism and excretion. The parent drug is the unchanged administered chemical entity, whereas metabolites are products of its biochemical transformation. These require separate consideration because disappearance of the parent drug need not mean disappearance of all drug-related material or pharmacological activity. Measurements may therefore distinguish the parent, individual metabolites, and total drug-related material. (ema.europa.eu)

The administered dose is the quantity delivered by a specified route, not necessarily the quantity entering systemic circulation as unchanged drug. An oral dose may be incompletely absorbed or metabolized in the intestine and liver before reaching that circulation. Systemic exposure describes the concentrations attained over time, usually measured in plasma or whole blood and summarized by quantities such as peak concentration and the area under the concentration–time curve. Exposure is consequently distinct from both the amount swallowed and the amount absorbed across the intestinal wall. For example, prescribing information for oral morphine reports bioavailability below 40% because of extensive presystemic metabolism. Morphine is the parent drug; morphine-3-glucuronide and morphine-6-glucuronide are metabolites, the latter having pharmacological activity. A parent-drug concentration alone therefore does not describe every potentially relevant circulating substance. (dailymed.nlm.nih.gov)

Within pharmacology, PK is complementary to pharmacodynamics (PD): PK concerns the relationship between dose and concentration over time, whereas PD concerns drug action and the relationship between concentration and biological response. Biopharmaceutics examines how drug-substance properties, dosage-form characteristics, and administration conditions influence drug release, absorption, and availability; it overlaps PK particularly at the interface between formulation and systemic exposure. Two formulations containing the same nominal dose can consequently produce different concentration–time profiles. Clinical pharmacology has a broader human focus, integrating PK and PD with evidence concerning therapeutic effects, adverse effects, interactions, and variation among patients. Exposure–response analysis connects these domains rather than making them interchangeable. (fda.gov)

A pharmacokinetic measurement is not itself a clinical outcome. A higher plasma concentration establishes greater exposure under the measurement conditions, not necessarily greater therapeutic benefit; nor does a low concentration establish safety. Interpretation depends on the relevant active substances, access to the site of action, concentration–response relationships, and the clinical circumstances. Changes in a biomarker likewise need not establish improvement in symptoms, function, or survival. PK evidence can explain differences between regimens and support their evaluation, but efficacy and safety conclusions require integration with pharmacodynamic, toxicological, and clinical evidence. The FDA’s 2003 exposure–response guidance explicitly treats exposure–response information as a component of drug development and regulatory assessment. (fda.gov)

The field encompasses human studies in healthy volunteers and patients, veterinary studies in the intended animal species, and nonclinical investigations supporting development. Veterinary interpretation must account for species-specific anatomy, physiology, and administration conditions; EMA’s revised target-animal PK guideline took effect on July 1, 2024. In safety studies, toxicokinetics applies pharmacokinetic measurements to characterize exposure and interpret toxicity findings. The FDA’s March 1995 ICH S3A guidance defines this use as generating PK data within nonclinical toxicity studies or specially designed supporting studies to assess systemic exposure and its relevance to clinical safety. Thus, toxicokinetics differs chiefly in study purpose and interpretive context, rather than constituting a separate set of disposition processes. (ema.europa.eu)

Historical development

Early quantitative studies treated drug concentrations as changing quantities governed by input, distribution, and removal, rather than merely as measurements accompanying an observed effect. In 1924, rather than 1928, Erik Widmark and J. Tandberg published equations corresponding to an open one-compartment model. Their treatment covered intravenous injection, repeated doses at uniform intervals, and constant-rate intravenous infusion. The essential simplification was to represent the body as a single kinetically homogeneous space from which substance could be removed. This made concentration–time relationships and accumulation under repeated administration mathematically tractable. (journals.sagepub.com)

In 1937, Torsten Teorell published two papers entitled Kinetics of Distribution of Substances Administered to the Body: the first addressed extravascular administration and the second intravascular administration. He formulated differential equations describing absorption, exchange between blood and tissues, and elimination. Transfer depended on concentration differences and permeability-related coefficients, giving the model a physiological interpretation rather than treating the concentration curve solely as an empirical mathematical function. His work provided foundations for both later compartmental analysis and physiologically based pharmacokinetic modeling (PBPK). It was nevertheless an antecedent of modern organ-resolved simulation, not an already complete version of it. (researchgate.net)

During the 1950s, quantitative disposition research increasingly connected mathematical analysis with pharmaceutical formulation and clinical measurements. Friedrich Hartmut Dost’s Der Blutspiegel appeared in 1953 and introduced the term Pharmakokinetik, systematically presenting one-compartment kinetics with different forms of drug input. Eino Nelson investigated dissolution-rate-controlled absorption, while Sidney Riegelman studied rectal absorption. By the 1960s, American schools and colleges of pharmacy were training researchers in pharmacokinetics and biopharmaceutics, alongside expanding industrial research. (journals.sagepub.com) Nelson’s 1961 review, Kinetics of Drug Absorption, Distribution, Metabolism, and Excretion, exemplified the consolidation of these processes into a common quantitative subject. (pubmed.ncbi.nlm.nih.gov) In 1964, John G. Wagner and Nelson demonstrated how blood concentrations and urinary excretion could be used to reconstruct absorption–time profiles and examine alternative absorption mechanisms. (onlinelibrary.wiley.com)

Computer-assisted analysis subsequently extended the field from describing individual experiments to estimating individual and population characteristics. In 1972, Lewis B. Sheiner, Barr Rosenberg, and Kenneth L. Melmon proposed combining routinely available clinical observations with subsequent blood measurements to refine individual pharmacokinetic predictions. (sciencedirect.com) A concrete demonstration of population pharmacokinetics followed in Sheiner and Stuart L. Beal’s 1980 comparison of estimation methods. They analyzed 124 steady-state phenytoin concentration–dosage pairs from 49 patients, distinguishing population-average kinetics, between-person variability, and residual variation. Their NONMEM approach jointly estimated these components instead of either pooling all observations as though patients were identical or fitting each patient separately before averaging the results. (pubmed.ncbi.nlm.nih.gov)

Mechanistic simulation developed along a complementary path. In 1971, Kenneth B. Bischoff, Robert L. Dedrick, David S. Zaharko, and James A. Longstreth published a methotrexate model with anatomical compartments including liver, kidneys, gastrointestinal tract, muscle, and plasma. It represented biliary excretion and partial intestinal reabsorption, using parameters measured directly or estimated from physiological principles for mice, rats, dogs, and humans. This illustrated how physiological structure could support predictions across species and dosing conditions, rather than merely reproduce a single plasma curve. (onlinelibrary.wiley.com)

Regulatory formalization came decades after these methodological foundations. The US Food and Drug Administration issued guidance on the format and content of PBPK submissions in 2018 and population-pharmacokinetic guidance in 2022. These documents addressed the presentation and application of established analytical approaches in drug development. The 2018 guidance explicitly distinguished reporting expectations from methodological best practices and stated that acceptance of PBPK results in place of clinical pharmacokinetic data would be decided case by case. (fda.gov)

Absorption and routes of administration

Drug absorption requires release from the dosage form and passage across biological barriers before entry into the circulation. In passive diffusion, movement follows a concentration gradient; membrane permeability depends on molecular size, lipid affinity, and ionization. For many weak acids and bases, the uncharged form crosses lipid membranes more readily, but local pH also affects aqueous solubility. Greater membrane permeability therefore does not necessarily produce greater absorption if little drug dissolves. Dissolution—the transfer of solid drug into solution—is distinct from solubility, the equilibrium concentration that can be dissolved; either dissolution or membrane passage can limit oral input. (sciencedirect.com)

Carrier-mediated uptake provides additional pathways across the intestinal epithelium. Such transport is substrate-selective and can become saturated, making absorption less than proportional to dose. Experiments reported in 1995 demonstrated proton-coupled uptake of the antibiotic cephalexin by expressed PEPT1, an intestinal peptide transporter. Efflux transporters, including P-glycoprotein and BCRP, oppose net absorption by transporting substrates toward the intestinal lumen. Consequently, intestinal permeability reflects both passive passage across the cell membrane and directional transport rather than lipid solubility alone. (pubmed.ncbi.nlm.nih.gov)

For oral drugs absorbed principally in the small intestine, gastric emptying controls when the dose reaches the absorptive region, whereas intestinal transit limits the time available for dissolution and uptake. Food can delay gastric emptying, change gastrointestinal pH, stimulate bile secretion, and interact with the drug or formulation; its net effect can increase, decrease, or delay systemic exposure. Absorption across the intestinal wall must also be distinguished from bioavailability: absorbed drug may undergo intestinal-wall metabolism and then hepatic extraction before reaching the systemic circulation. These presystemic losses constitute the first-pass effect, so complete intestinal uptake need not imply complete systemic availability. (fda.gov)

Sublingual administration allows uptake through oral mucosa into systemic venous drainage, avoiding initial portal delivery for the fraction absorbed there; swallowed drug instead follows the gastrointestinal route. The 2017 Nitrostat label reports peak nitroglycerin concentrations approximately 6–7 minutes after sublingual administration and absolute bioavailability of about 40%, illustrating that avoiding hepatic first passage does not guarantee complete availability. Rectal administration only partly avoids hepatic first passage because rectal drainage includes both portal and systemic pathways. Inhaled drugs enter through respiratory surfaces, but systemic exposure can also include an orally absorbed contribution from material deposited in the mouth and subsequently swallowed. (accessdata.fda.gov)

Transdermal delivery requires passage through the skin and can sustain input rather than produce a rapid peak. With fentanyl patches, drug accumulates in an upper-skin depot; serum concentrations generally level off after 12–24 hours, and absorption continues after patch removal. Intramuscular and subcutaneous injections likewise require movement from an extravascular site into blood or lymph, with input affected by tissue perfusion and formulation release. Solutions and depot preparations therefore need not have similar absorption profiles. Intravenous administration, by contrast, places drug directly in the circulation: it has no absorption phase, although an infusion can still control the rate of input. (dailymed.nlm.nih.gov)

Absorption rate and extent are separate properties. Slower input can delay the peak and reduce its height without reducing total exposure when systemic availability and clearance remain unchanged. Delayed-release formulations postpone release, whereas prolonged-release formulations spread it over time. If absorption is slower than elimination, the terminal concentration decline may reflect continuing absorption rather than intrinsic elimination. In a simple first-order model, this flip-flop kinetics occurs when $k_a < k_e$, and the apparent terminal half-life approaches $\ln(2)/k_a$. An intravenous reference can help distinguish the processes: a study of rectal ropivacaine in 32 volunteers found longer terminal half-lives after rectal than intravenous administration, indicating absorption-dependent decline. (ema.europa.eu)

Distribution and tissue access

Distribution depends on both delivery by the circulation and passage across vascular and cellular barriers. When membrane passage is rapid, tissue uptake is perfusion-limited: well-perfused organs equilibrate faster than poorly perfused tissues such as resting adipose tissue. When passage is slow, distribution is permeability-limited, even if blood supply is abundant. Capillary structure, molecular size, ionization, and partitioning into membrane lipids determine these restrictions. Lipid solubility can facilitate passage through a cell membrane, but does not by itself establish tissue exposure: uptake transporters can concentrate substrates, whereas efflux transporters can oppose entry or accelerate exit. The rate of equilibration and the eventual tissue-to-plasma concentration ratio are therefore distinct properties. (gastroplus.slp-software.com)

In plasma, drugs bind reversibly to albumin, α₁-acid glycoprotein, and lipoproteins. Acidic drugs commonly bind extensively to albumin, whereas many basic drugs bind to α₁-acid glycoprotein. Total concentration includes bound and unbound drug; the unbound fraction is $f_{u,p}=C_{u,p}/C_{p,\mathrm{total}}$. Binding and dissociation continuously replenish the unbound pool, which generally supplies drug for passive membrane passage. A change in binding can consequently alter total concentration without producing a proportional change in unbound exposure. Binding is not necessarily constant across concentrations or physiological conditions, so a total concentration cannot always be converted to an unbound concentration using a fixed percentage. (merckmanuals.com)

Blood-cell association creates a further distinction between plasma and whole-blood measurements. Tacrolimus, for example, associates strongly with erythrocytes as well as plasma proteins; its blood-to-plasma distribution depends on hematocrit, drug concentration, plasma protein concentration, and the temperature during plasma separation. Its prescribing information therefore identifies whole blood as the more appropriate sampling matrix for describing its pharmacokinetics. Plasma and whole-blood concentrations are not interchangeable measurements, and any volume or clearance calculated from them must retain the corresponding concentration basis. (accessdata.fda.gov)

Within tissues, reversible binding to proteins, membranes, and other cellular components can retain drug after circulating concentrations fall. Lipid partitioning and intracellular pH differences can also produce sequestration; weak bases may accumulate in acidic intracellular compartments through ion trapping. Such accumulation increases total tissue concentration without necessarily increasing the unbound concentration available at a particular target. Digoxin illustrates substantial tissue uptake: its prescribing information describes a 6–8-hour distribution phase and notes that early high serum concentrations do not represent concentrations at its sites of action. (pro-s3.mhem2.magento.prod.mheducation.com)

Access to the central nervous system is restricted by the blood–brain barrier, whose endothelial tight junctions limit passage between cells. Transcellular permeability and efflux systems, especially P-glycoprotein, then govern access for many small molecules. In 1994, Alfred H. Schinkel and colleagues demonstrated increased brain exposure to substrate drugs in mice lacking the mdr1a P-glycoprotein gene. Restricted sites are not uniformly inaccessible: entry depends on the compound and barrier involved, including blood–cerebrospinal-fluid and blood–retinal barriers. Cerebrospinal-fluid concentration is therefore not automatically equivalent to unbound brain interstitial concentration. Likewise, a tissue homogenate combines extracellular, intracellular, and bound drug rather than directly measuring target-site exposure. (pubmed.ncbi.nlm.nih.gov)

The apparent volume of distribution relates the amount of drug in the body, $A$, to a specified reference concentration, commonly total plasma concentration:

It is a proportionality quantity, expressed in litres or litres per kilogram, not an anatomical space. Extensive tissue retention lowers plasma concentration relative to body amount and can produce a volume exceeding the body's physical volume; digoxin labeling reports approximately 475–500 L. Conversely, predominant confinement to circulating plasma tends to give a smaller volume. The numerical value depends on the sampled matrix and the distribution state or model used: it neither identifies which tissues contain the drug nor demonstrates that a restricted target site has been reached. (merckmanuals.com)

Drug metabolism

Drug metabolism chemically transforms a parent compound into one or more metabolites through enzyme-catalysed reactions. Phase I reactions include oxidation, reduction, and hydrolysis: oxidation can introduce hydroxyl groups or remove alkyl groups; reduction can convert carbonyl groups to alcohols; hydrolysis cleaves susceptible bonds using water. Phase II reactions conjugate a drug or metabolite with groups derived from endogenous donors, as in glucuronidation, sulfation, and glutathione conjugation. These labels classify reactions rather than obligatory successive stages. A parent drug with an appropriate functional group can undergo conjugation directly, while other compounds undergo several parallel or sequential transformations. Morphine, for example, can be glucuronidated at its existing hydroxyl groups without prior oxidation. (accessdata.fda.gov)

The liver is a major metabolic organ, but drug-metabolizing systems also occur in the intestine, kidneys, lungs, and skin. The cytochrome P450 family includes CYP3A4, CYP2D6, CYP2C9, CYP2C19, and CYP1A2, which have overlapping but distinct substrate preferences. Their reactions include hydroxylation and oxidative dealkylation; intestinal CYP activity can transform an orally administered drug before it reaches the systemic circulation. Non-CYP systems include flavin-containing monooxygenases, esterases, and conjugating enzymes such as UDP-glucuronosyltransferases and sulfotransferases. Consequently, metabolic clearance cannot be equated with CYP activity alone, and the contribution of each pathway depends on both the compound and the tissue. (fda.gov)

Metabolism does not necessarily inactivate a drug. Morphine-3-glucuronide lacks morphine’s analgesic activity, whereas morphine-6-glucuronide is pharmacologically active. In 1997, Brian L. Coffman and colleagues demonstrated that recombinant human UGT2B7 catalysed morphine glucuronidation, identifying a specific enzyme underlying this direct phase II pathway. Metabolic activation also occurs with a prodrug: enalapril undergoes hydrolysis of its ethyl ester to produce enalaprilat, the active angiotensin-converting enzyme inhibitor. Thus, disappearance of the parent compound need not represent disappearance of pharmacological activity. (pubmed.ncbi.nlm.nih.gov)

Reactive metabolites differ from stable active or inactive products because they can react with cellular constituents. Acetaminophen undergoes glucuronidation and sulfation, but a smaller oxidative pathway, principally involving CYP2E1, produces the reactive intermediate N-acetyl-p-benzoquinone imine (NAPQI). NAPQI normally undergoes rapid glutathione conjugation and subsequent transformation into cysteine and mercapturic acid conjugates. This illustrates how oxidative bioactivation and conjugative detoxification can operate within the metabolism of the same drug; conjugation is not simply a stage that follows every phase I reaction. (accessdata.fda.gov)

Hepatic extraction connects metabolic capacity with delivery of drug in blood. The extraction ratio is $E_H=(C_{\mathrm{in}}-C_{\mathrm{out}})/C_{\mathrm{in}}$, using flow-weighted inflowing and outflowing blood concentrations, and hepatic blood clearance is $CL_H=Q_HE_H$. For a simplified, metabolism-only, well-stirred liver with rapid equilibration of unbound drug and nonsaturating metabolism,

where $Q_H$ is hepatic blood flow, $f_{u,b}$ is the unbound fraction in blood, and $CL_{\mathrm{int}}$ is intrinsic metabolic clearance referenced to unbound concentration. Intrinsic clearance expresses metabolic capacity independently of blood-flow delivery. When $f_{u,b}CL_{\mathrm{int}}\gg Q_H$, clearance approaches blood flow; when $f_{u,b}CL_{\mathrm{int}}\ll Q_H$, it approaches $f_{u,b}CL_{\mathrm{int}}$. Blood and plasma binding measures must therefore be used consistently. Restricted cellular uptake, biliary transport, or enzyme saturation requires a more elaborate description than this simplified relationship. (ema.europa.eu)

Excretion and elimination pathways

Elimination encompasses both metabolism, which converts a parent drug into other chemical species, and excretion, which transfers unchanged drug or metabolites out of the body. Disappearance of the parent compound therefore does not imply that all drug-related material has left the organism: metabolites may remain in circulation before undergoing further transformation or excretion. Conversely, unchanged drug recovered in feces after oral administration may never have been absorbed and therefore need not represent elimination from the systemic circulation. Regulatory assessments distinguish these processes by measuring parent drug, metabolites, and, where appropriate, total drug-related material separately. (ema.europa.eu)

The kidneys handle drugs through glomerular filtration, tubular secretion, and tubular reabsorption. For a freely filterable small molecule, filtration acts on drug unbound to plasma proteins; its filtration clearance, expressed relative to total plasma concentration, is approximately $f_{u,p}\times GFR$, where $f_{u,p}$ is the unbound fraction and $GFR$ is the glomerular filtration rate. Active secretion moves drug from peritubular blood through tubular cells into urine. Transporters involved include organic anion transporters OAT1 and OAT3 and organic cation transporters such as OCT2, with additional transport systems mediating exit across the urine-facing membrane. These pathways are substrate-selective, can become saturated, and can be inhibited by competing compounds; protein-bound drug may contribute after dissociating from its binding sites. (pmc.ncbi.nlm.nih.gov)

Reabsorption returns drug from tubular fluid to blood, opposing urinary loss. Passive reabsorption generally favors lipid-soluble, nonionized molecules and depends on membrane permeability, urine flow, and urinary pH. More alkaline urine increases the ionization of weak acids, generally reducing their passive reabsorption; weak bases show the opposite tendency. Thus, renal excretion is the net outcome of filtration and secretion minus reabsorption, rather than a direct measure of filtration alone. The FDA’s March 2024 renal-function guidance explicitly identifies these processes, together with renal metabolism, as determinants of renal drug handling. (pmc.ncbi.nlm.nih.gov)

Biliary excretion transfers parent drug or metabolites from hepatocytes into bile and subsequently into the intestine. Material remaining in the intestinal lumen can leave in feces, whereas reabsorbed material undergoes enterohepatic recirculation. Intestinal deconjugation can regenerate an absorbable parent compound from a glucuronide metabolite. Mycophenolic acid illustrates this mechanism: its glucuronide participates in recirculation, and secondary plasma concentration peaks commonly occur 6–12 hours after dosing. In a study involving 12 healthy volunteers, pretreatment with cholestyramine, which interrupts recirculation, reduced mycophenolic-acid exposure by approximately 40%. Fecal recovery alone cannot quantify biliary excretion after an oral dose because unabsorbed drug contributes to the same sample. (dailymed.nlm.nih.gov)

Pulmonary excretion is particularly important for volatile anesthetics. Sevoflurane’s low blood solubility facilitates rapid elimination through the lungs after administration stops. Sweat, saliva, and breast milk usually make smaller contributions to whole-body drug removal; nevertheless, milk transfer can produce exposure in a nursing infant even when its contribution to maternal elimination is minor. (dailymed.nlm.nih.gov)

Clearance expresses removal relative to the corresponding drug concentration, with units such as milliliters per minute or liters per hour. Renal excretory clearance concerns unchanged drug entering urine; hepatic clearance encompasses hepatic metabolism and biliary removal of the parent compound. Total-body clearance combines the contributions of distinct elimination pathways. These contributions must use a consistent concentration reference—plasma or whole blood—and must not double-count successive events: hepatic conversion of parent drug followed by urinary excretion of its metabolite is not two independent clearances of the parent. Nonrenal clearance also need not be exclusively hepatic, because other tissues can metabolize drugs. (pmc.ncbi.nlm.nih.gov)

Concentration–time profiles and pharmacokinetic parameters

Peak concentration, $C_{\max}$, is the highest observed concentration in a specified sampling matrix; $T_{\max}$ is the elapsed time from administration to that peak. Both depend on sampling times: an unobserved peak between samples may exceed the reported $C_{\max}$. Trough concentration is the minimum concentration within a dosing interval, commonly approximated by a sample immediately before the next dose. These measurements must identify the analyte and matrix—for example, unchanged drug in plasma rather than a metabolite in whole blood. The area under the concentration–time curve, AUC, measures integrated exposure:

Its units combine concentration and time, such as mg·h/L. $\mathrm{AUC}_{0-\infty}$ includes exposure extrapolated beyond observation, whereas $\mathrm{AUC}_{0-\tau}$ covers a dosing interval of length $\tau$. Equal AUCs need not imply equal peaks or identical profile shapes. (fda.gov)

Clearance, $CL$, is the rate of irreversible drug elimination divided by the corresponding concentration: $CL=R_{\mathrm{elim}}/C$. Its units are volume per time, such as L/h—not mass per time. Plasma-based and blood-based clearances therefore require their respective concentrations. With constant systemic clearance, complete intravenous delivery, and eventual elimination of the entire dose $D_{\mathrm{iv}}$, integrating the elimination rate gives

This mass-balance result does not require a one-compartment distribution model. For extravascular administration with systemic availability $F$, dose divided by AUC instead estimates apparent clearance, $CL/F$. (pubmed.ncbi.nlm.nih.gov)

The terminal rate constant, $\lambda_z$, is the positive magnitude of the slope of the late, approximately straight segment of a plot of $\ln C$ against time. During that segment, $C(t)$ declines approximately as an exponential function, and the terminal half-life is $t_{1/2,z}=\ln(2)/\lambda_z$. An earlier rapid decline can reflect tissue distribution as well as elimination and should not be substituted for the terminal slope. Conversely, a slow terminal decline can reflect drug returning from tissues; after extravascular administration it may instead be controlled by slow absorption. Terminal half-life is consequently not, by itself, a measure of the body's elimination capacity. (ema.europa.eu)

For a linear one-compartment system with constant distribution volume $V$, the amount $A=VC$ obeys $dA/dt=-CL\,C=-(CL/V)A$. Thus the elimination rate constant is $CL/V$, giving

In a multicompartment system, the corresponding terminal relationship uses the terminal volume $V_z=CL/\lambda_z$, not automatically the steady-state volume $V_{\mathrm{ss}}$. The latter describes the amount-to-concentration ratio when distribution has equilibrated under constant input. As a hypothetical calculation, $CL=5$ L/h and $V_z=50$ L yield a terminal half-life of approximately 6.93 h. (pubmed.ncbi.nlm.nih.gov)

Mean residence time, MRT, describes the average time drug molecules spend in the body before elimination. For an intravenous bolus under the usual linear, time-invariant disposition assumptions,

An infusion requires correction for input duration; an extravascular profile additionally includes absorption time. MRT equals $1/\lambda_z$ for monoexponential disposition, but generally not for multiexponential profiles. Leslie Z. Benet and Ronald L. Galeazzi established the noncompartmental determination of $V_{\mathrm{ss}}$ in 1979. (pubmed.ncbi.nlm.nih.gov)

Absolute bioavailability compares systemic delivery of unchanged drug after an extravascular dose with intravenous delivery; relative bioavailability compares two formulations or routes:

These calculations require comparable analyte measurements, adequately characterized AUCs, and unchanged systemic clearance between conditions; dose normalization additionally assumes dose-proportional exposure over the doses compared. Relative availability can exceed 100% without implying that more than the administered dose entered circulation. Hypothetically, an oral 100-mg dose producing 20 mg·h/L and an intravenous 50-mg dose producing 25 mg·h/L give $F_{\mathrm{abs}}=0.40$, or 40%. (ema.europa.eu)

Repeated administration and nonlinear kinetics

Repeated administration produces accumulation when drug remaining from earlier doses contributes to concentrations after later doses. With constant, linear kinetics, concentrations approach a reproducible pattern: intermittent dosing produces recurring peaks and troughs, whereas continuous infusion approaches a constant concentration. At steady state, systemic input equals elimination over each dosing interval, not necessarily at every instant. For a one-compartment model with instantaneous intravenous doses separated by interval $\tau$, the steady-state peak is the first-dose peak multiplied by the accumulation factor

where $k$ is the first-order elimination rate constant. The peak-to-trough ratio is $e^{k\tau}$; shorter intervals therefore reduce fluctuation when the total input per unit time is held constant. These expressions do not directly describe delayed absorption or multicompartment distribution. (arxiv.org)

In the same one-compartment model, an infusion started from zero approaches its plateau according to $C(t)=C_{\mathrm{ss}}(1-e^{-kt})$. After four and five half-lives, it reaches 93.75% and 96.875% of the plateau, respectively—not an exact steady state. The plateau depends on input rate and clearance: $C_{\mathrm{ss}}=R_0/CL$, where $R_0$ is the intravenous infusion rate. For repeated doses $D$ with constant bioavailability $F$, the average steady-state concentration is

Thus, dose per interval determines average exposure, while input timing also determines fluctuation. These relationships follow from the linear mass-balance model. (arxiv.org)

A loading dose supplies an initial amount intended to establish a specified concentration promptly; maintenance administration replaces drug subsequently eliminated. In a simplified, rapidly equilibrating one-compartment model, these concepts correspond to $D_{\mathrm L}=VC_{\mathrm{target}}/F$ and a maintenance input rate of $CL\,C_{\mathrm{target}}/F$. Loading therefore depends principally on the relevant distribution volume, whereas maintenance depends on clearance. This distinction does not mean that loading accelerates elimination or establishes tissue equilibrium immediately. Actual concentration profiles also depend on administration duration and distribution; intravenous dexmedetomidine studies, for example, have combined loading administration with constant maintenance infusions to characterize exposure. These are pharmacokinetic concepts rather than patient-specific dosing instructions. (arxiv.org)

First-order elimination removes a constant fraction per unit time, so elimination rate is proportional to concentration. Capacity-limited elimination can instead be represented by Michaelis–Menten kinetics:

Here $v$ is an amount eliminated per unit time, $V_{\max}$ is maximum elimination capacity, and $K_m$ is the concentration giving half that capacity. When $C\ll K_m$, $v\approx(V_{\max}/K_m)C$, approximating first-order behavior. When $C\gg K_m$, $v\approx V_{\max}$, approximating zero-order behavior: an almost constant amount, rather than fraction, disappears per unit time. Apparent clearance, $v/C=V_{\max}/(K_m+C)$, consequently decreases as concentration rises. Phenytoin illustrates this dose-dependent nonlinearity: saturation of its hepatic hydroxylation can make relatively small dose increments produce disproportionately large concentration increases. (doi.org)

Dose dependence differs from time dependence, in which disposition changes during continued exposure even without a dose change. In autoinduction, a drug increases the metabolic capacity responsible for its own elimination. Carbamazepine labeling reports initial half-lives of 25–65 hours, decreasing to 12–17 hours with repeated administration, with autoinduction completed after approximately 3–5 weeks of a fixed regimen. Conversely, autoinhibition reduces a drug’s own metabolic clearance; esomeprazole is a time-dependent inhibitor of CYP2C19, a mechanism identified in its labeling as contributing to nonlinear pharmacokinetics. Such changes can oppose or amplify ordinary accumulation. (dailymed.nlm.nih.gov)

Simple superposition—adding time-shifted single-dose profiles—requires linear, time-invariant kinetics. Saturation violates proportionality, while induction or inhibition makes successive doses encounter different elimination capacity. A fixed “four to five half-lives” rule therefore fails when half-life varies with concentration or treatment duration. Under constant infusion with Michaelis–Menten elimination as the only removal pathway, mass balance gives $C_{\mathrm{ss}}=R_0K_m/(V_{\max}-R_0)$ only when $R_0<V_{\max}$; no finite steady state exists in that idealized model when input equals or exceeds maximum elimination capacity. The EMA guideline accordingly calls for experimental verification of accumulation predicted from single-dose studies and investigation of dose dependence during multiple dosing. (doi.org)

Study design and bioanalytical measurement

Single-dose studies characterize exposure after one administration; multiple-dose studies examine accumulation, steady-state profiles, and changes with repeated administration. An intravenous-reference study compares intravenous and extravascular exposure to establish absolute bioavailability, with appropriate dose normalization. Healthy volunteers permit controlled assessment without many disease-related influences, whereas patients are studied when disease may alter disposition or drug toxicity makes healthy-volunteer participation inappropriate. Food-effect studies commonly use randomized crossover designs, allowing each participant to receive the same oral product under fed and fasted conditions after an adequate washout. Meal composition, fasting duration, water intake, and administration relative to the meal are standardized. (ema.europa.eu)

Sampling schedules are matched to the expected concentration–time profile rather than spaced uniformly. Predose samples establish baseline or residual concentrations; closely spaced early samples characterize absorption and rapid distribution, while later samples define the terminal decline. Multiple-dose studies include trough measurements and sampling across a dosing interval. Actual administration and collection times, including infusion start and stop times, must be recorded: deviations from nominal times can distort estimated peak concentrations and elimination rates. Sampling duration and assay sensitivity are interdependent, because late samples cannot characterize the terminal phase if concentrations fall below the validated quantification range. (ema.europa.eu)

The sampled matrix determines what exposure is measured. Plasma excludes blood cells, whereas whole blood includes drug associated with erythrocytes; their concentrations are therefore not interchangeable. Timed urine collections measure excreted amounts when concentration is combined with collection volume. Tissue samples provide site-specific information but require a separately justified sampling and analytical strategy. Mass-balance studies commonly administer a carbon-14-labelled drug and collect urine and feces to quantify recovery. Total radioactivity measures labelled parent drug plus labelled metabolites, not unchanged drug alone; chromatographic separation and structural analysis distinguish these components. The FDA’s July 2024 mass-balance guidance recommends generally at least six evaluable participants and aims for recovery exceeding 90% of administered radioactivity, while recognizing circumstances requiring different collection endpoints. (ema.europa.eu)

Liquid chromatography–tandem mass spectrometry separates analytes and measures selected precursor-to-product ion transitions, often using an isotope-labelled internal standard. Ligand-binding assays instead exploit molecular recognition, commonly using antibodies to quantify therapeutic proteins. Validation establishes selectivity against interfering matrix components, accuracy, precision, calibration over the reportable range, and analyte stability. ICH M10, adopted in 2022, specifies chromatographic validation accuracy generally within ±15% of nominal concentration and precision no greater than 15% coefficient of variation; the corresponding limits at the lower limit of quantification are 20%. Ligand-binding assays generally use 20% limits, widening to 25% at the lower and upper quantification limits. These are assay-validation criteria, not permissible uncertainty in clinical outcomes. (fda.gov)

Independent ethics review and documented informed consent address the procedures, risks, and burden of participation. Blood volume, collection frequency, overnight stays, radiation exposure, and invasive tissue sampling require explicit consideration; ICH E6(R3), adopted in January 2025, emphasizes participant burden and scientifically justified trial procedures. Specimen handling must preserve the quantity being measured: collection tubes and anticoagulants, time to plasma separation, storage temperature, transport, and freeze–thaw cycles are controlled within validated stability conditions. Sample identifiers, processing records, analytical batches, quality-control results, protocol deviations, and reasons for repeat analysis provide a traceable record supporting reproducibility. (database.ich.org)

Noncompartmental analysis

Noncompartmental analysis (NCA) estimates exposure and disposition parameters directly from concentration–time observations without fitting an explicit arrangement of kinetic compartments. Its central operation is numerical integration: for successive measurements $C_i$ and $C_{i+1}$, the linear trapezoidal contribution is

Summing these contributions gives the area through the last quantifiable measurement, $\mathrm{AUC}_{0-t_{\mathrm{last}}}$. For positive, declining concentrations, logarithmic trapezoids instead assume exponential change between observations:

Linear-up/log-down integration combines linear interpolation on rising intervals with logarithmic interpolation on falling intervals. These choices impose local interpolation assumptions, even though no compartmental structure is specified. (certara.com)

The terminal rate constant, $\lambda_z$, is estimated by linear regression of $\ln C$ against time over a selected terminal interval; it is the negative of the fitted slope. Automated selection commonly compares regressions containing at least three late observations, but a high adjusted $R^2$ does not establish that the observations represent the terminal phase. With exponential decline continuing beyond the last measurement,

Some implementations substitute the terminal regression’s predicted concentration for the observed $C_{\mathrm{last}}$; that choice should be identified. The associated terminal half-life is $\ln(2)/\lambda_z$. (onlinehelp.certara.com)

The extrapolated fraction $f_{\mathrm{ext}}$ indicates how much total exposure depends on an unobserved tail rather than measured concentrations. For illustration, an observed AUC of $80\ \mathrm{mg\,h/L}$, $C_{\mathrm{last}}=2\ \mathrm{mg/L}$, and $\lambda_z=0.10\ \mathrm{h^{-1}}$ yield a total AUC of $100\ \mathrm{mg\,h/L}$, with 20% extrapolated. Large fractions make total AUC especially sensitive to terminal-slope errors. The EMA’s 2021 veterinary bioequivalence guideline uses observed coverage of at least 80% of total AUC as a sampling benchmark; this context-specific criterion is not proof that the terminal slope is correct. (onlinehelp.certara.com)

For an intravenous dose $D$, clearance is calculated as $CL=D/\mathrm{AUC}_{0-\infty}$, assuming linear, time-invariant disposition. After extravascular administration, the corresponding estimate is apparent clearance, $CL/F=D/\mathrm{AUC}_{0-\infty}$, where $F$ is systemic bioavailability. Without independent information about $F$, reduced bioavailability cannot be distinguished from increased clearance. Terminal volume is derived as $V_z=CL/\lambda_z$, or $V_z/F$ after extravascular dosing. Its interpretation therefore depends on the terminal decline representing disposition rather than prolonged absorption; numerical calculation alone does not establish an anatomical distribution volume. (onlinehelp.certara.com)

Statistical-moment analysis, described by K. Yamaoka, T. Nakagawa, and T. Uno in 1978, additionally uses the first-moment area, $\mathrm{AUMC}=\int_0^\infty tC(t)\,dt$. For an intravenous bolus in a linear system, mean residence time is $\mathrm{MRT}=\mathrm{AUMC}/\mathrm{AUC}$; for a constant-rate infusion lasting $T$, the systemic residence-time estimate subtracts $T/2$. The conventional relation $V_{\mathrm{ss}}=CL\times\mathrm{MRT}$ requires additional assumptions, notably elimination from the sampled central space. Oral MRT includes input time: its difference from intravenous-bolus MRT estimates mean absorption time only when systemic disposition is unchanged between routes. Because AUMC weights concentrations by time, late measurements and extrapolation have greater influence than on AUC. (pubmed.ncbi.nlm.nih.gov)

Sparse sampling can miss peaks, bridge substantial curvature, or leave too few observations to characterize terminal decline. Below-quantification results are not measured zeros; their treatment affects the integration endpoint and potentially the terminal regression. Comparisons across studies also depend on matching sampling windows, analytical sensitivity, specimen matrix, feeding conditions, and dosing state. Actual collection times, integration rules, terminal-point selection, extrapolated fractions, and handling of unquantifiable concentrations are therefore material parts of an NCA result, not merely software settings. (onlinehelp.certara.com)

Compartmental models

A compartment represents a kinetically homogeneous drug pool: its contents are assumed to mix instantaneously, so that a single concentration describes the pool at each time. A one-compartment model treats the measured disposition as occurring within one such pool; two- and multicompartment models introduce additional pools with distinguishable exchange rates. These are kinetic abstractions, not necessarily individual organs. The central compartment receives intravenous input and usually supplies the modeled plasma concentration; peripheral compartments represent drug exchanging with it. A peripheral compartment may aggregate several tissues, while a fitted central volume need not equal anatomical plasma volume. Different model structures can therefore reproduce the same measured concentration profile without establishing the underlying tissue arrangement. (pmc.ncbi.nlm.nih.gov)

The governing differential equations express conservation of mass. For a conventional linear two-compartment model with elimination restricted to the central compartment,

where $A_c,A_p$ are drug amounts, $C_c=A_c/V_c$, and $C_p=A_p/V_p$. Here $V_c,V_p$ are apparent volumes, $CL$ is elimination clearance, and $Q$ is intercompartmental clearance; both clearances have units of volume per time. The exchange terms cancel when the equations are added, leaving $d(A_c+A_p)/dt=R_{\mathrm{in}}-CL\,C_c$: redistribution changes location but does not itself eliminate drug. Equivalent transfer-rate constants are $k_{cp}=Q/V_c$ and $k_{pc}=Q/V_p$, which generally differ despite sharing the same $Q$. (pmc.ncbi.nlm.nih.gov)

An ideal intravenous bolus of dose $D$ is represented by the initial conditions $A_c(0^+)=D$, $A_p(0)=0$, followed by zero input. Infusion instead supplies a specified $R_{\mathrm{in}}(t)$, constant during a constant-rate infusion and zero after its termination. A simple extravascular model adds an absorption depot:

where $k_a$ is the first-order absorption constant and $F$ is systemic bioavailability. In the one-compartment intravenous-bolus limit, these assumptions give $C(t)=(D/V)e^{-(CL/V)t}$. More elaborate inputs can represent delayed absorption or formulation-controlled delivery without changing the disposition compartments. (pmc.ncbi.nlm.nih.gov)

For the linear two-compartment bolus model, central concentration is biexponential:

The coefficients and slopes depend jointly on transfer, elimination, and volumes. Although the faster phase is commonly called the distribution phase and the slower phase the terminal phase, neither exponential generally represents a single isolated process: elimination occurs during early distribution, and return from peripheral pools can influence terminal decline. Additional compartments can generate multiexponential profiles. The number of phases distinguishable in observations also depends on sampling times and measurement precision, rather than simply counting anatomical tissue groups. (pmc.ncbi.nlm.nih.gov)

Parameter estimation fits predicted concentrations to observations, commonly through weighted nonlinear regression or maximum likelihood estimation with an explicit residual-error model. Estimates of $CL,V_c,Q,V_p$, and absorption parameters should be accompanied by uncertainty measures. Model selection considers residual patterns, parameter precision, physiological plausibility, and improvements in fit relative to added complexity; a lower fitting error alone does not justify another compartment. The FDA’s February 2022 population-pharmacokinetics guidance explicitly distinguishes structural-model specification, estimation, diagnostic evaluation, and reporting of parameter uncertainty, although these principles also apply to individual-profile models. (pmc.ncbi.nlm.nih.gov)

Structural identifiability asks whether ideal, noise-free observations under the specified input and measurement scheme could uniquely determine model parameters. Practical identifiability asks whether the actual data constrain them sufficiently: missing early samples, for example, can leave rapid exchange poorly characterized. A separate problem is model indistinguishability, in which different structures produce identical observable outputs. In 1994, Keith R. Godfrey, Michael J. Chapman, and Sándor Vajda examined two-compartment examples with linear and Michaelis–Menten elimination, including uncertainty about which compartment contained an elimination pathway. Consequently, a mathematically adequate plasma fit does not uniquely locate elimination or prove a biological mechanism; additional inputs or measurements may be needed to discriminate competing explanations. (pubmed.ncbi.nlm.nih.gov)

Population pharmacokinetics

Population pharmacokinetic analyses use nonlinear mixed-effects models to estimate typical disposition parameters and distinguish several sources of variability. Fixed effects describe typical clearance, distribution volumes, and covariate relationships; random effects describe unexplained differences between people and, when repeated treatment periods are observed, between occasions within one person. Residual error represents remaining observation-level discrepancies, including analytical error and model inadequacy. These components are not interchangeable: Mats O. Karlsson and Lewis B. Sheiner demonstrated in 1993, using simulations and two real-data examples, that ignoring between-occasion variability could bias population estimates and produce spurious period effects. (ema.europa.eu)

An illustrative clearance model is

where $CL_{\mathrm{typ}}(\mathbf{x}_{ik})$ is typical clearance conditional on covariates, $\eta_i$ is a person-specific random effect, and $\kappa_{ik}$ is an occasion-specific effect. The random effects are commonly modeled as zero-mean normal variables on the logarithmic scale, keeping clearance positive. Their variances describe heterogeneity, not uncertainty in the estimated typical clearance. An observation model can separately combine proportional and additive residual errors. Estimation fits the population structure jointly rather than treating independently fitted individual curves as equally precise observations. (pubmed.ncbi.nlm.nih.gov)

Sparse measurements from many participants can be analyzed together with intensively sampled profiles, including data pooled across studies. This does not remove the need for informative sampling design: observations distributed across absorption, peak exposure, and later decline help distinguish parameters that trough-only measurements may not identify. Accurate dose histories and actual sampling times remain essential. Covariates commonly include body size, renal function, age, and concomitant treatments. Their inclusion requires biological justification, adequate representation across the observed range, and assessment of effect magnitude and uncertainty—not statistical significance alone. Correlated predictors, such as age and renal function, can complicate attribution; an estimated association does not itself establish a physiological mechanism or causation. (fda.gov)

Individual parameters can subsequently be estimated through Bayesian inference, combining the fitted population distribution with that person’s concentrations. Empirical Bayes estimates generally condition on estimated population parameters. When individual observations contain little information, random-effect estimates move toward zero and individual parameters toward covariate-adjusted typical values: this is shrinkage. In their 2009 simulation study, Radojka M. Savic and Mats O. Karlsson showed that shrinkage could conceal or generate apparent covariate relationships and weaken individual-prediction diagnostics. Their standard-deviation-based measure was $1-\operatorname{SD}(\hat{\eta})/\omega$, where $\omega$ is the estimated population standard deviation. Values exceeding approximately 20–30% warranted particular caution in that study, rather than constituting a universal rejection threshold. (pubmed.ncbi.nlm.nih.gov)

Evaluation combines complementary methods. Observed-versus-predicted plots and weighted residuals against time or prediction reveal systematic discrepancies. Visual predictive checks compare observed concentration percentiles with distributions generated by repeated simulations under the study design; stratification by dose, age, or sampling scheme can expose failures hidden by pooled plots. Subject-level bootstrap resampling, retaining each selected participant’s observations together, assesses parameter stability and supports confidence intervals, but does not independently demonstrate predictive validity. Evaluation against participants or studies excluded from model development provides a separate test of transportability. The FDA’s February 2022 guidance emphasizes that model adequacy is purpose-dependent: acceptable overall fit does not establish reliable prediction in every subgroup or justify extrapolation beyond evaluated conditions. (ema.europa.eu)

Physiologically based pharmacokinetic modeling

Physiologically based pharmacokinetic (PBPK) models represent organs or tissue groups as compartments connected according to blood circulation, rather than as abstract spaces inferred solely from concentration–time curves. Organ volumes, blood flows, tissue composition, and drug-specific partition coefficients determine distribution. For a well-mixed, perfusion-limited tissue without local elimination, conservation of mass gives

where $V_i$ is tissue volume, $C_i$ is tissue concentration, $Q_i$ is blood flow, and $K_{i:b}$ is the equilibrium tissue-to-blood concentration ratio. The outflow concentration is therefore $C_i/K_{i:b}$. Eliminating organs require additional metabolic or excretory terms. Blood-based and plasma-based partition coefficients must be distinguished and, where necessary, connected through the blood-to-plasma concentration ratio. (ema.europa.eu)

Perfusion-limited distribution assumes that exchange across tissue barriers is sufficiently rapid for blood delivery to control uptake. Permeability-limited models instead distinguish vascular and extravascular spaces, with transfer governed by a permeability–surface-area product and concentration gradients. These structures can represent restricted access to the central nervous system or slow passage across cellular membranes. Carrier-mediated uptake and efflux may require directional, saturable transport terms; intracellular metabolism can then compete with drug returning to blood. Consequently, reduced hepatic uptake and reduced metabolic activity need not produce equivalent changes in blood and intracellular concentrations, even when both reduce overall clearance. (ema.europa.eu)

In vitro–in vivo extrapolation connects laboratory measurements with the physiological model. Intrinsic metabolic clearance measured in liver microsomes or hepatocytes can be scaled using microsomal protein or cell abundance and liver mass, with corrections for unbound drug in the incubation and blood. Enzyme-specific contributions, transporter measurements, solubility, and intestinal permeability provide additional inputs. These quantities are combined with physiological information rather than treated as direct measurements of whole-body clearance. In a 2016 study, Hoa Q. Nguyen and colleagues combined metabolic measurements, passive-diffusion clearances measured in cultured human hepatocytes, and liver blood flow to predict midazolam-metabolite exposure. The analysis explicitly considered the fraction of metabolite escaping its formation site into systemic circulation. (pubmed.ncbi.nlm.nih.gov)

Applications include predicting enzyme- or transporter-mediated drug interactions and distinguishing route-dependent exposure: an oral model can include dissolution, intestinal transit, absorption, and intestinal and hepatic first-pass loss, whereas intravenous input bypasses these processes. Interspecies translation replaces anatomical and physiological inputs while retaining, measuring, or re-estimating relevant drug-specific properties; it is not simply dose scaling by body weight. Models of children, organ impairment, or pregnancy similarly require changes to the relevant physiological processes. In 2012, Gaohua and colleagues modeled caffeine, metoprolol, and midazolam as substrates of CYP1A2, CYP2D6, and CYP3A4, respectively. Their pregnancy model predicted the reported pharmacokinetic changes within twofold of observed values, while identifying broader elimination mechanisms as requiring further evaluation. (ema.europa.eu)

Qualification is specific to an intended application: platform performance across relevant reference drugs and scenarios is distinct from evaluation of an individual drug model. The FDA’s 2018 reporting guidance calls for documented parameter sources, assumptions, model modifications, verification, and uncertainty analyses; the EMA guideline effective July 1, 2019 likewise distinguishes platform qualification from drug-model predictive performance. Sensitivity analysis tests how uncertain inputs—such as intestinal availability, intrinsic clearance, or transporter abundance—alter predicted exposure. Independent concentration–time and interaction datasets provide stronger predictive tests than reuse of calibration data. Agreement with plasma observations alone does not establish correct tissue concentrations or uniquely identify the underlying mechanism; extrapolations to unevaluated routes, populations, or interacting drugs require evidence relevant to those conditions. (fda.gov)

Sources of variation among individuals

Development changes drug clearance through both growth and maturation: increasing body mass enlarges organs, whereas maturation changes their functional capacity. In neonates, glomerular filtration, tubular secretion, and individual metabolic pathways develop at different rates; therefore, clearance cannot generally be inferred by multiplying an adult value by the infant-to-adult weight ratio. Gestational age and postnatal age provide distinct information, particularly after premature birth. The FDA’s 2022 neonatal guidance accordingly identifies body size and developmental age as separate pharmacokinetic covariates. In older adults, reduced renal function, altered body composition, and coexisting disease must likewise be distinguished from chronological age itself; aging does not uniformly reduce every elimination pathway. (fda.gov)

During pregnancy, expansion of plasma volume and body water can increase distribution volumes, while increased renal filtration can accelerate elimination of susceptible drugs. Changes in metabolic activity are pathway-specific, rather than a general acceleration of metabolism, and vary across gestation. Maternal exposure, fetal exposure, and exposure through breast milk are separate measurements: fetal concentrations depend on placental transfer and fetal disposition, not simply maternal plasma concentrations. After birth, milk concentrations determine the amount ingested only when combined with milk intake; the infant’s systemic exposure additionally depends on gastrointestinal absorption and its own clearance. A milk-to-plasma concentration ratio alone therefore does not quantify infant systemic exposure. (fda.gov)

Kidney disease can reduce elimination of unchanged drug and renally cleared metabolites, but its effects extend beyond filtration. Uremia can alter protein binding and hepatic or intestinal metabolism and transport, affecting drugs with predominantly nonrenal clearance. In cirrhosis, reduced metabolic capacity, altered hepatic perfusion, portosystemic shunting, and reduced albumin synthesis can affect different components of disposition. Lower albumin may increase the unbound fraction without producing a proportional increase in unbound exposure, because distribution and clearance can change simultaneously. Total and unbound concentrations are consequently not interchangeable indicators of exposure when binding differs substantially between individuals. (fda.gov)

Critical illness can produce variation in either direction. Renal dysfunction reduces elimination, whereas some critically ill patients develop augmented renal clearance despite apparently normal plasma creatinine. In a 2014 multicenter observational study, Andrew Udy and colleagues used repeated eight-hour urinary creatinine collections to characterize this phenomenon rather than relying on plasma creatinine alone. Body composition creates another distinction between size and function: equal body weights need not imply equal distribution volumes. In a 1975 study, Ulrich Klotz and colleagues found that diazepam’s terminal half-life increased with age alongside changes in distribution volume, without a corresponding age-related decline in clearance in the healthy participants studied. A longer half-life thus need not identify slower elimination capacity. (doi.org)

Inherited variation affects both metabolic enzymes and transporters. CYP2D6 poor metabolizers form less morphine from codeine, whereas ultrarapid metabolizers can form it more rapidly; reduced-function SLCO1B1 variants are associated with higher systemic simvastatin exposure. Such relationships are drug-specific: reduced enzyme activity may increase exposure to a parent drug but decrease exposure to a metabolite. A genotype-inferred metabolic phenotype is not a complete prediction of observed disposition, because organ function, concurrent medicines, and other environmental influences also contribute. Genetic ancestry or demographic labels cannot substitute for an individual’s relevant variants and physiological characteristics. (fda.gov)

Sex-related physiological differences, body composition, diet, smoking, and administration history require similarly specific interpretation rather than fixed group-wide assumptions. Meal timing and composition can alter absorption through gastric emptying and other gastrointestinal processes. Smoking changes enzyme activity: in a 2004 study, Mirko Faber and Uwe Fuhr observed a 36.1% decrease in caffeine clearance after cessation of heavy smoking, demonstrating that an environmental exposure can change disposition within the same person. Recorded dose, missed administrations, elapsed time since the preceding dose, and relation to meals must also be distinguished from biological variability when interpreting concentration measurements. (fda.gov)

Pharmacokinetic drug interactions

A pharmacokinetic drug interaction occurs when one drug changes another drug’s absorption, distribution, metabolism, or excretion, altering exposure to the parent compound or its metabolites. A pharmacodynamic interaction instead changes the response to a combination without necessarily changing drug concentrations. The drug producing the pharmacokinetic change is termed the precipitant or interacting drug; the drug whose disposition changes is the object or affected drug. These roles are relationship-specific: a compound can affect another drug while also being susceptible to interactions itself. ICH M12, issued as final FDA guidance in August 2024, harmonized evaluation of enzyme- and transporter-mediated interactions during drug development. (fda.gov)

Reversible enzyme inhibition depends on inhibitor concentration at the enzyme and generally diminishes as the inhibitor is removed. Time-dependent inhibition becomes stronger with incubation or exposure time; when it involves enzyme inactivation, recovery depends partly on enzyme replacement rather than simply on inhibitor elimination. Enzyme induction increases enzyme expression, commonly through transcriptional regulation, so its onset and disappearance depend on protein turnover. Inhibiting metabolism can increase parent-drug exposure while decreasing formation of a metabolite; induction can produce the opposite pattern. Consequently, parent and active-metabolite concentrations may require separate interpretation. Rifampin illustrates overlapping mechanisms: a single administration can inhibit hepatic OATP1B uptake transporters, whereas repeated administration induces CYP3A activity. (fda.gov)

Transporter inhibition can affect intestinal absorption, hepatic uptake, or renal secretion. Inhibition of intestinal P-glycoprotein, an efflux transporter, can increase absorption of susceptible substrates; inhibition of hepatic OATP1B1 or OATP1B3 can reduce liver uptake and increase circulating exposure. Digoxin is a commonly used P-glycoprotein probe, while statins such as pravastatin are used in OATP studies. Transporter probes are not necessarily pathway-specific: several statins also undergo transport by BCRP, complicating attribution of an observed interaction to one transporter alone. (fda.gov)

Absorption-related interactions need not involve enzymes or transporters. Acid-reducing drugs raise gastric pH, potentially lowering the solubility and dissolution of weak bases and thereby reducing bioavailability. Luminal binding or chelation can prevent drug uptake: magnesium- or aluminum-containing antacids can reduce ciprofloxacin bioavailability by as much as 90%. Changes in gastrointestinal transit provide another mechanism. Semaglutide delays gastric emptying and can therefore influence oral-drug absorption, although a change in absorption rate does not establish a clinically important change in total exposure for every coadministered medicine. (fda.gov)

Dedicated studies usually compare exposure to the affected drug alone with exposure during coadministration. The AUC ratio, $R_{\mathrm{AUC}}=\mathrm{AUC}_{\mathrm{combination}}/\mathrm{AUC}_{\mathrm{alone}}$, quantifies the change in overall systemic exposure; corresponding peak-concentration ratios describe changes in $C_{\max}$. Sensitive index substrates, such as midazolam for CYP3A, help detect pathway inhibition, while index inhibitors provide reproducible inhibition of the pathway under study. Strong CYP inhibitors increase a sensitive index substrate’s AUC at least fivefold; moderate inhibitors increase it twofold to less than fivefold. These classifications describe interaction magnitude, not clinical severity, which also depends on the affected drug’s exposure–response relationship. (fda.gov)

Laboratory experiments identify metabolic pathways, measure inhibition, and test induction or transporter effects; dedicated clinical studies directly measure the resulting exposure change under specified conditions. Population analyses can evaluate concomitant medicines within larger trials, but their informativeness depends on sampling and reliable medication histories. Mechanistic static models and physiologically based simulations combine pathway contributions with inhibitor or inducer exposure to predict untested combinations. Combined inhibition, induction, and transport effects may reinforce or oppose one another. Predictions therefore depend on experimentally supported mechanisms and parameter estimates; uncertainty increases when important pathways or concentrations at interaction sites are poorly characterized. (fda.gov)

Therapeutic proteins and complex drug products

Therapeutic proteins are generally degraded by proteolytic enzymes to peptides and amino acids rather than eliminated through the oxidative pathways characteristic of many small-molecule drugs. Smaller proteins may undergo renal filtration and subsequent tubular uptake and degradation, whereas large monoclonal antibodies are poorly filtered. After subcutaneous administration, larger proteins reach the circulation substantially through the lymphatic system; degradation at the injection site and during transport can reduce bioavailability. Their size and limited membrane permeability restrict distribution largely to vascular and interstitial spaces, with limited passive access to intracellular targets and the central nervous system. These distinctions are addressed in the European Medicines Agency’s 2007 guideline on therapeutic-protein pharmacokinetics. (ema.europa.eu)

Binding to a pharmacological target can itself become an elimination pathway. In target-mediated drug disposition, high-affinity binding followed by internalization and degradation removes drug from circulation. Because target abundance is finite, this pathway can become saturated: increasing dose may then produce a more-than-proportional increase in exposure and decreasing apparent clearance. Changes in target expression or turnover can also change disposition during treatment. Consequently, target abundance in patients—for example, receptor overexpression in tumors—can limit extrapolation from healthy-volunteer pharmacokinetics. (ema.europa.eu)

For immunoglobulin G–based products, neonatal Fc receptor (FcRn) recycling counteracts intracellular degradation. Following cellular uptake, IgG binds FcRn in acidic endosomes, is diverted from lysosomal destruction, and returns to the cell surface, where near-neutral pH favors release. Fc engineering can extend this process without requiring a change in target specificity. In a randomized study of 31 healthy adults reported in 2013, the investigational antibody motavizumab-YTE, containing three Fc substitutions, showed a two- to fourfold longer serum half-life than unmodified motavizumab, reaching approximately 100 days. Increased FcRn affinity in the acidic endosome must remain compatible with release at the cell surface. (pmc.ncbi.nlm.nih.gov)

Antidrug antibodies can accelerate clearance through immune-complex removal, delay clearance, or have no measurable pharmacokinetic effect; neutralization of biological activity is a separate question from altered elimination. Exposure therefore requires interpretation alongside the timing, magnitude, and persistence of the antibody response. Analytical interference adds another distinction: antidrug antibodies may alter recovery in drug-concentration assays, while circulating therapeutic protein can mask antibodies in immunogenicity assays. A measured concentration change may thus reflect altered disposition, altered assay detection, or both; assays measuring free and antibody-bound drug need not yield equivalent profiles. (fda.gov)

An antibody–drug conjugate comprises molecular species whose concentration–time profiles can diverge as payload is released and the antibody is degraded. Relevant analytes include conjugated antibody, total antibody—including conjugated and unconjugated forms—released, unconjugated payload, and pharmacologically active metabolites. Changing drug-to-antibody ratios further complicate interpretation: antibody concentration alone does not necessarily describe the amount of attached payload. The US Food and Drug Administration’s March 2024 guidance calls for characterization of the conjugate and its constituent parts from early clinical development, with later omission of particular measurements justified by their pharmacological relevance, detectability, and correlation with other analytes. Released payload may undergo renal or hepatic elimination independently of antibody catabolism. (fda.gov)

Therapeutic oligonucleotides present a different separation between circulating and active exposure. Chemical stabilization and delivery conjugates influence tissue uptake and persistence; internalized material may remain sequestered in endosomes rather than reach cytoplasmic or nuclear targets. Total tissue concentration therefore does not equal pharmacologically accessible intracellular concentration. (journals.sagepub.com) Inclisiran illustrates the temporal distinction: its N-acetylgalactosamine conjugate facilitates hepatocyte uptake, where its small interfering RNA directs breakdown of PCSK9 messenger RNA. The 2024 US prescribing information reports an approximately nine-hour plasma terminal half-life and undetectable plasma concentrations within 24–48 hours, while LDL-cholesterol reduction persisted for months after a single administration. Disappearance from plasma is therefore not equivalent to loss of intracellular pharmacological activity. (accessdata.fda.gov)

Linking exposure to response and clinical monitoring

Pharmacokinetic–pharmacodynamic (PK–PD) models connect a concentration–time profile with a biomarker, therapeutic effect, or adverse effect. Exposure may be represented by instantaneous concentration, cumulative area under the curve (AUC), or another measure appropriate to the response. A direct, saturable relationship can be expressed as $E(C)=E_0+E_{\max}C/(EC_{50}+C)$, where $E_0$ is baseline response, $E_{\max}$ is the maximum drug-related increment, and $EC_{50}$ is the concentration producing half that increment. Beneficial and adverse effects can have different concentration–response curves and time courses. A measured biomarker response is not, by itself, evidence of improved clinical outcome; the FDA’s May 2003 exposure–response guidance distinguishes biomarkers, surrogate endpoints, and clinical endpoints. (fda.gov)

An effect may lag behind plasma exposure because drug equilibration with its site of action takes time. An effect-compartment model represents this delay through $dC_e/dt=k_{e0}(C_p-C_e)$, where $C_p$ is plasma concentration, $C_e$ is a hypothetical effect-site concentration, and $k_{e0}$ controls equilibration. Alternatively, an indirect-response model describes drug inhibition or stimulation of the production or loss of a biological mediator. Natalie Dayneka, Varun Garg, and William Jusko formalized four such basic models in 1993. For example, inhibition of mediator production allows the response to develop according to mediator turnover rather than tracking plasma concentration immediately. Plotting response against plasma concentration can therefore produce a hysteresis loop: the same concentration corresponds to different responses during rising and falling exposure. Such a loop describes a time-dependent concentration–effect relationship, not necessarily a change in drug elimination. (pmc.ncbi.nlm.nih.gov)

For antibacterial agents, exposure is commonly related to the minimum inhibitory concentration (MIC), the concentration preventing visible bacterial growth under specified laboratory conditions. Principal indices include $fAUC_{24}/MIC$, the 24-hour unbound-drug AUC divided by MIC; $fC_{\max}/MIC$, the unbound peak-to-MIC ratio; and $fT_{>MIC}$, the percentage of a dosing interval during which unbound concentration exceeds MIC. Their relevance is drug-dependent: time above MIC is particularly important for beta-lactams, AUC/MIC for fluoroquinolones, and peak/MIC is an important index for aminoglycosides. Target values also depend on the organism, infection model, and endpoint, such as bacterial stasis versus bacterial killing; they are not universal thresholds applicable across antibiotics. (ema.europa.eu)

Therapeutic drug monitoring combines measured concentrations with administration history and clinical information to interpret exposure. A concentration is meaningful only in relation to its sampling time: a post-infusion specimen and a predose trough represent different portions of the profile. A trough may serve as an exposure surrogate, but different concentration–time profiles can produce similar troughs and different AUCs. As a specific historical example, the 2020 ASHP–IDSA–PIDS–SIDP vancomycin consensus guideline favored AUC-based monitoring for serious methicillin-resistant Staphylococcus aureus infections and specified an $AUC_{24}$ range of 400–600 mg·h/L when assuming an MIC of 1 mg/L. That range concerns the guideline’s defined setting, not a general antibacterial target. (ashp.org)

Model-informed individual exposure estimation can combine a population model with a patient’s observations through Bayesian inference. The population parameter distribution supplies prior information; measured concentrations, exact administration times, and sampling times update the individual parameter distribution and estimated AUC. Sparse sampling nevertheless leaves estimates dependent on the prior model, assay error, and how well the model represents the individual. The 2020 vancomycin guideline specifically identified uncertainty about trough-only Bayesian estimation in populations poorly represented in validation data, including patients with unstable renal function. A model-derived exposure is therefore an estimate rather than a directly observed complete concentration–time curve. (ashp.org)

Population exposure–response associations do not automatically establish causation. The FDA’s 2003 guidance notes that exposure comparisons can be confounded by patient characteristics affecting both disposition and response. Disease-related reduction in clearance can increase exposure while independently predicting a poor outcome; an association between high exposure and poor outcome may consequently contain confounding as well as a drug effect. Randomizing administered dose does not itself randomize the exposure subsequently achieved. Interpretation therefore requires attention to baseline prognostic factors, temporal ordering, and whether exposure preceded the response rather than changing as a consequence of illness. (fda.gov)

Drug development, bioequivalence, and regulatory interpretation

Pharmacokinetic evidence supports selection of doses and dosing intervals for clinical trials by identifying the exposures produced by candidate regimens, their accumulation, and their variability. Exposure–response analyses connect these estimates with efficacy and adverse-effect observations; exposure alone does not establish clinical benefit. Pharmacokinetic comparisons also bridge formulations used at different development stages—for example, an early capsule and a tablet intended for marketing—and support evaluation of manufacturing changes after approval. Bridging between populations requires additional assumptions: matching adult exposure in children is informative only when the relevant disease course and exposure–response relationships justify extrapolation, with safety assessed separately. FDA’s 2003 exposure–response guidance describes these uses in development and regulatory decisions. (fda.gov)

Bioequivalence studies compare the rate and extent of availability of the same active substance from test and reference products. For systemically acting products, the principal measurements are generally the area under the concentration–time curve, $AUC$, and maximum concentration, $C_{\max}$. A randomized, two-period crossover study gives each participant both products in different periods, separated by a washout, allowing within-person comparison. A parallel design assigns different participants to each product and can be appropriate when a long elimination half-life makes crossover impractical. Selection of fasting or fed conditions depends on formulation characteristics and applicable requirements. FDA adopted ICH M13A in October 2024 for immediate-release solid oral dosage forms; on May 28, 2026, it also announced final guidance on pharmacokinetic-endpoint studies for abbreviated new drug applications and on statistical approaches to bioequivalence. (fda.gov)

In conventional average bioequivalence analysis, $AUC$ and $C_{\max}$ are logarithmically transformed, and the estimated test-minus-reference difference is exponentiated to obtain a geometric mean ratio. The entire 90% confidence interval for each required ratio must fall within 80.00–125.00% in applicable studies. These reciprocal limits are symmetric on the logarithmic scale; they are not permission for tablets to contain 80–125% of the labeled amount. As a hypothetical illustration, a ratio of 98% with an interval of 92–105% satisfies this criterion, whereas the same ratio with an interval of 79–122% does not. Neither a point estimate near 100% nor a nonsignificant conventional difference test establishes equivalence. (fda.gov)

Acceptance rules are not universal. EMA specifies a narrowed 90.00–111.11% interval for both $AUC$ and $C_{\max}$ in ciclosporin comparisons because both measures matter for its narrow therapeutic index. Under specified conditions, highly variable products may instead qualify for reference-variability-based widening of the $C_{\max}$ limits using replicate designs. Other alternatives concern the evidence required rather than simply changing statistical limits: qualifying immediate-release products may receive a biopharmaceutics-classification-system-based waiver of an in vivo study, supported by solubility, permeability, dissolution, and formulation evidence. Modified-release and locally acting products require consideration of their particular delivery characteristics; plasma exposure may not adequately represent local availability. (ema.europa.eu)

Regulatory interpretation translates these findings into product information. FDA’s labeling guidance places clinically relevant disposition data in subsection 12.3, including exposure at approved dosages, accumulation, absorption, distribution, elimination, specific populations, and interaction-study results. These data provide the evidential basis for relevant statements elsewhere in labeling, rather than functioning as prescribing rules in isolation. Important limits remain: blood measurements may imperfectly represent target-tissue exposure, population extrapolation depends on the groups studied, and animal-to-human predictions depend on physiological and drug-specific assumptions. For model-based submissions, FDA’s 2018 reporting guidance calls for parameter sources, assumptions, software details, electronic model files, verification against observed data, and sensitivity analyses. Such documentation supports reproducibility and assessment of fitness for a particular regulatory question; successful prediction in one setting does not establish validity in another. (fda.gov)

References

1. Pharmacokinetic Studies in Manema.europa.eu
2. DailyMed — Morphine Sulfate tabletdailymed.nlm.nih.gov
3. Exposure-Response Relationships — Study Design, Data Analysis, and Regulatory Applicationsfda.gov
4. Guidance Recap Podcast — Bioavailability Studies Submitted in NDAs or INDs: General Considerationsfda.gov
5. Conduct of pharmacokinetic studies in target animal species — Scientific guidelineema.europa.eu
6. S3A Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studiesfda.gov
7. Kinetics of drug absorption, distribution, metabolism, and excretionpubmed.ncbi.nlm.nih.gov
8. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.pubmed.ncbi.nlm.nih.gov
9. Physiologically Based Pharmacokinetic Analyses — Format and Content Guidance for Industryfda.gov
10. Population Pharmacokineticsfda.gov
11. Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlationsfda.gov
12. Differential recognition of beta-lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2pubmed.ncbi.nlm.nih.gov
13. Is oral absorption of vigabatrin carrier-mediated?pubmed.ncbi.nlm.nih.gov
14. Essential Elements of BCS III-Based Biowaiver Requestfda.gov
15. Food-Effect Bioavailability and Fed Bioequivalence Studiesfda.gov
16. Nitrostat Labelaccessdata.fda.gov
17. Rectal bioavailability of lidocaine in man: partial avoidance of "first-pass" metabolismpubmed.ncbi.nlm.nih.gov
18. Pulmonary Drug Delivery and Bioequivalence Presentationfda.gov
19. Fentanyl Transdermal System CIIdailymed.nlm.nih.gov
20. Duragesic Prescribing Informationaccessdata.fda.gov
21. Pharmacokinetics Equationsgastroplus.slp-software.com
22. Goodman & Gilman’s: The Blood-Brain Barrier and Its Influence on Drug Transport to the Brainpro-s3.mhem2.magento.prod.mheducation.com
23. Drug Distribution to Tissuesmerckmanuals.com
24. Prograf (tacrolimus) capsules/injection labelaccessdata.fda.gov
25. Tacrolimus prescribing informationaccessdata.fda.gov
26. Digoxin prescribing informationaccessdata.fda.gov
27. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugspubmed.ncbi.nlm.nih.gov
28. Digoxin tablets prescribing informationdailymed.nlm.nih.gov
29. Telaprevir clinical pharmacology reviewaccessdata.fda.gov
30. PowerPoint Presentationfda.gov
31. In Vitro Metabolism- and Transporter-Mediated Drug-Drug Interaction Studies Guidance for Industryfda.gov
32. Human UGT2B7 catalyzes morphine glucuronidationpubmed.ncbi.nlm.nih.gov
33. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducersfda.gov
34. Tarceva biopharmaceutics reviewaccessdata.fda.gov
35. Fexinidazole multidisciplinary reviewaccessdata.fda.gov
36. Enalapril prescribing informationaccessdata.fda.gov
37. Morphine glucuronosyltransferase activity in human liver microsomes is inhibited by a variety of drugs that are co-administered with morphinepubmed.ncbi.nlm.nih.gov
38. Acetaminophen injection prescribing informationaccessdata.fda.gov
39. Additional Supporting Documentation – System Parameters and Compound Filesema.europa.eu
40. Annex 6: Response to EMA, 26 June 2024ema.europa.eu
41. Clinical Pharmacology and Biopharmaceutics Review—Vandetanibaccessdata.fda.gov
42. Measurement of renal function during drug developmentpmc.ncbi.nlm.nih.gov
43. Rolapitant: Other Reviewaccessdata.fda.gov
44. Pharmacokinetics in Patients with Impaired Renal Function—Study Design, Data Analysis, and Impact on Dosingfda.gov
45. Mycophenolate Mofetil, USPdailymed.nlm.nih.gov
46. Sevoflurane, USP Volatile Liquid for Inhalationdailymed.nlm.nih.gov
47. Drug Excretion—Merck Manual Professional Editionmerckmanuals.com
48. There is Only One Valid Definition of Clearance: Critical Examination of Clearance Concepts Reveals the Potential for Errors in Clinical Drug Dosing Decisionslink.springer.com
49. The Extended Clearance Concept Following Oral and Intravenous Dosing: Theory and Critical Analysespmc.ncbi.nlm.nih.gov
50. Bioavailability Studies Submitted in NDAs or INDs – General Considerationsfda.gov
51. Guideline on the conduct of pharmacokinetic studies in target animal speciesema.europa.eu
52. Clearance concepts in pharmacokineticspubmed.ncbi.nlm.nih.gov
53. Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimenspmc.ncbi.nlm.nih.gov
54. Clearance (née Rowland) concepts: a downdate and an updatepubmed.ncbi.nlm.nih.gov
55. Noncompartmental determination of the steady-state volume of distributionpubmed.ncbi.nlm.nih.gov
56. Statistical moments in pharmacokineticspubmed.ncbi.nlm.nih.gov
57. Statistical moments in pharmacokinetics: models and assumptionspubmed.ncbi.nlm.nih.gov
58. Clinical pharmacology and pharmacokinetics: questions and answers - Scientific guidelineema.europa.eu
59. What should patients do if they miss a dose of medication? A theoretical approacharxiv.org
60. Aminophylline Injection, USP prescribing informationdailymed-beta.nlm.nih.gov
61. PRECEDEX prescribing informationaccessdata.fda.gov
62. Michaelis-Menten from an In Vivo Perspective: Open Versus Closed Systemsdoi.org
63. Phenytoin Sodium ERdailymed.nlm.nih.gov
64. CARBAMAZEPINEdailymed.nlm.nih.gov
65. NEXIUM I.V. prescribing informationaccessdata.fda.gov
66. Assessing the Effects of Food on Drugs in INDs and NDAs — Clinical Pharmacology Considerationsfda.gov
67. Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies Guidance for Industryfda.gov
68. M10 Bioanalytical Method Validation and Study Sample Analysisfda.gov
69. ICH E6(R3) Guidelinedatabase.ich.org
70. How to calculate AUC (Linear and Log-linear)certara.com
71. Noncompartmental Analysis: Computational rulesonlinehelp.certara.com
72. Noncompartmental Analysis: Parameter formulasonlinehelp.certara.com
73. Guideline on the conduct of bioequivalence studies for veterinary medicinal products, revision 2ema.europa.eu
74. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral eliminationpubmed.ncbi.nlm.nih.gov
75. Theoretical Examination Seeking Tangible Physical Meanings of Slopes and Intercepts of Plasma Concentration–Time Relationships in Minimal Physiologically Based Pharmacokinetic Modelspmc.ncbi.nlm.nih.gov
76. Statistical Identifiability and Convergence Evaluation for Nonlinear Pharmacokinetic Models with Particle Swarm Optimizationpmc.ncbi.nlm.nih.gov
77. Population Pharmacokinetics: Guidance for Industryfda.gov
78. Identifiability and indistinguishability of nonlinear pharmacokinetic modelspubmed.ncbi.nlm.nih.gov
79. Identifiable pharmacokinetic models: the role of extra inputs and measurementspubmed.ncbi.nlm.nih.gov
80. Population Pharmacokinetics: Guidance for Industryfda.gov
81. Guideline on reporting the results of population pharmacokinetic analysesema.europa.eu
82. The importance of modeling interoccasion variability in population pharmacokinetic analysespubmed.ncbi.nlm.nih.gov
83. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutionspubmed.ncbi.nlm.nih.gov
84. Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulationema.europa.eu
85. Physiologically Based Pharmacokinetic Analyses — Format and Content Guidance for Industryfda.gov
86. Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Datapubmed.ncbi.nlm.nih.gov
87. Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic modelpubmed.ncbi.nlm.nih.gov
88. A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4pubmed.ncbi.nlm.nih.gov
89. Reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation - Scientific guidelineema.europa.eu
90. General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Productsfda.gov
91. E7 Studies in Support of Special Populations: Geriatrics — Questions and Answersfda.gov
92. Pharmacokinetics in Pregnancy — Study Design, Data Analysis, and Impact on Dosing and Labelingfda.gov
93. Clinical Lactation Studies: Considerations for Study Designfda.gov
94. Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosagefda.gov
95. Augmented Renal Clearance in the ICUdoi.org
96. The effects of age and liver disease on the disposition and elimination of diazepam in adult manpubmed.ncbi.nlm.nih.gov
97. Table of Pharmacogenetic Associationsfda.gov
98. Studies in Support of Special Populations: Geriatricsfda.gov
99. M12 Drug Interaction Studiesfda.gov
100. M12 Drug Interaction Studiesfda.gov
101. M12 Drug Interaction Studies: Questions and Answersfda.gov
102. Drug Interaction Information in Human Prescription Drug and Biological Product Labeling | Guidance for Industryfda.gov
103. Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications Guidance for Industryfda.gov
104. DailyMed — CIPROFLOXACIN — ciprofloxacin hydrochloride tablet, film coateddailymed.nlm.nih.gov
105. OZEMPIC (semaglutide) injection: prescribing informationdailymed.nlm.nih.gov
106. Guideline on the Clinical Investigation of the Pharmacokinetics of Therapeutic Proteinsema.europa.eu
107. A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adultspmc.ncbi.nlm.nih.gov
108. pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG Recyclingpmc.ncbi.nlm.nih.gov
109. Immunogenicity Assessment for Therapeutic Protein Productsfda.gov
110. Immunogenicity Testing of Therapeutic Protein Products — Developing and Validating Assays for Anti-Drug Antibody Detectionfda.gov
111. Clinical Pharmacology Considerations for Antibody-Drug Conjugates: Guidance for Industryfda.gov
112. LEQVIO (inclisiran) injection: US prescribing informationaccessdata.fda.gov
113. Exposure-Response Relationships — Study Design, Data Analysis, and Regulatory Applicationsfda.gov
114. Comparison of Four Basic Models of Indirect Pharmacodynamic Responsespmc.ncbi.nlm.nih.gov
115. Physiologic indirect response models characterize diverse types of pharmacodynamic effectspubmed.ncbi.nlm.nih.gov
116. Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal productsema.europa.eu
117. M13A Bioequivalence for Immediate-Release Solid Oral Dosage Formsfda.gov
118. FDA publishes two final guidances for industry: “Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA” and “Statistical Approaches to Establishing Bioequivalence”content.govdelivery.com
119. Clinical pharmacology and pharmacokinetics: questions and answers - Scientific guidelineema.europa.eu
120. Clinical Pharmacology Section of Labeling for Human Prescription Drug and Biological Products — Content and Format Guidance for Industryfda.gov
121. Physiologically Based Pharmacokinetic Analyses — Format and Content Guidance for Industryfda.gov
122. Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPKpmc.ncbi.nlm.nih.gov